Anti-CTLA-4 immunotherapy effect on αSMA+ myofibroblast late-depleted pancreatic ductal adenocarcinoma model - - GEO DataSets

Summary

Format

Summary
Summary (text)
Unique Identifier List

Send to:

Choose Destination

File
Clipboard
Collections

Links from GEO Profiles

Anti-CTLA-4 immunotherapy effect on αSMA+ myofibroblast late-depleted pancreatic ductal adenocarcinoma model

Analysis of pancreatic ductal adenocarcinoma (PDAC) tumors from PKT; αSMA-tk+ transgenics injected daily with ganciclovir at 6 weeks of age for 10 days or less to deplete αSMA+ myofibroblasts and treated with anti-CTLA4. Results provide insight into molecular basis of anti-CTLA4 therapy in PDAC.

Organism:: Mus musculus

Type:: Expression profiling by array, count, 2 agent, 2 protocol sets

Platform:: GPL6887
Series:: GSE52812
9 Samples

Download data

DataSet

Accession:: GDS5822

ID:: 5822

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Supplemental Content

GEO DataSets

Functional Genomics Studies

Result Filters

Send to:

Links from GEO Profiles

Supplemental Content

Related information

Important Links

Recent activity